STOCK TITAN

Corbus Pharmaceuticals Holdings Inc - CRBP STOCK NEWS

Welcome to our dedicated news page for Corbus Pharmaceuticals Holdings (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corbus Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corbus Pharmaceuticals Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
Corbus Pharmaceuticals Holdings Inc

Nasdaq:CRBP

CRBP Rankings

CRBP Stock Data

373.24M
6.77M
1.76%
56.68%
0.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Norwood

About CRBP

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunabâ„¢, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.